Masimo Launches MightySat Pulse Oximeter for Personal Use - Analyst Blog

Masimo Corporation ( MASI ) - a global provider of innovative non-invasive monitoring technologies - has launched MightySat fingertip pulse oximeter designed for personal use at the Consumer Electronics Show (CES) in Las Vegas.

Masimo's pulse oximeter delivers accurate oxygen saturation and pulse rate measurements. These two parameters provide an indication of lung and heart efficiency and are being increasingly measured with fingertip pulse oximeters for personal use. Masimo's MightySat is an ideal device for those who want reliable measurements even under extreme conditions.

Notably, MightySat is the first fingertip pulse oximeter available with Masimo SET Measure-through Motion and Low Perfusion pulse oximetry. It is also the only fingertip pulse oximeter available with the optional Pleth Variability Index (PVI), a measure of the dynamic changes in the perfusion index (PI) that occur during one or more complete respiratory cycles.

Masimo's SET technology has outperformed all pulse oximetry technologies with dramatically fewer false measurements during motion and low perfusion (or low blood flow) to the finger in more than 100 independent and objective studies. This data further validates MightySat's efficacy and measurement accuracy.

MightySat is available in three versions, each of which provides oxygen saturation, pulse rate and perfusion index measurements. The device has a compact, battery-powered design with a large color screen that can be rotated for real-time display of the pleth waveform as well as measurements.

Additionally, MightySat has an optional Bluetooth wireless functionality which enables measurement display via a free, downloadable app on iOS and Android mobile devices as well as the ability to trend and communicate measurements.

Last month, Masimo received 510(k) clearance from the U.S. Food and Drug Administration (FDA) as well as CE Mark approval for its ISA OR+ multigas monitoring module. The device supports anesthesia agent identification and ventilation management. Following the approvals, the company announced a global launch of the module.

Masimo continues to introduce new products which include O3 regional oximetry, iSpO2 Mobile health pulse oximeter for Android, Radius-7 wearable wireless Rainbow Pulse Co-Oximeter and respiration monitor and the Rainbow DCI-mini SpHb sensor for infants and small children. We believe Masimo's innovative product line will drive top-line growth going forward.

However, reluctance of hospitals on buying new technology remains a major headwind. Moreover, the monitoring products market remains quite competitive with a lot of companies vying for substantial market share. Masimo faces stiff competition from Covidien ( COV ).

Currently, Masimo carries a Zacks Rank #3 (Hold).

Better-ranked stocks in the medical instruments industry include Synergetics USA ( SURG ) and Abiomed ( ABMD ). While Synergetics sports a Zacks Rank #1 (Strong Buy), Abiomed carries a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

MASIMO CORP (MASI): Free Stock Analysis Report

COVIDIEN PLC (COV): Free Stock Analysis Report

ABIOMED INC (ABMD): Free Stock Analysis Report

SYNERGETICS USA (SURG): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

Learn More